Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims align with the provided FDA label excerpt for indications and mechanism of action; however, several claims include additional specifics not supported by the supplied label text (e.g., 'need systemic therapy' and prescriber-set dosing schedule) and one claim is not supported at all by the provided sections.
Category Scores
Accurate Statements
Adbry is used in adults when atopic dermatitis is not adequately controlled with topical prescription therapies.
1 INDICATIONS AND USAGE: indicated for moderate-to-severe atopic dermatitis in adults ... whose disease is not adequately controlled with topical prescription therapies ...
Adbry is an injectable medicine (subcutaneous injection; prefilled syringe/autoinjector).
11 DESCRIPTION and/or 1 (section header present): 'ADBRY (tralokinumab-ldrm) injection' and 'for subcutaneous use' with prefilled syringe/autoinjector
Unsupported Statements
Adbry (tralokinumab) is used to treat moderate-to-severe atopic dermatitis (eczema) in adults who need systemic therapy.
The provided Indications section does not use or state 'need systemic therapy'; it specifies not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Adbry is specifically for atopic dermatitis (the most common form of eczema).
The provided label excerpt identifies treatment of atopic dermatitis but does not support the assertion that atopic dermatitis is 'the most common form of eczema.'
Adbry is not a treatment for every type of rash.
The provided label excerpt does not contain any statement addressing whether Adbry treats or does not treat other types of rash.
Adbry is taken on a dosing schedule set by the prescriber for moderate-to-severe atopic dermatitis.
The provided label excerpt does not include dosing instructions or a statement that dosing schedule is set by the prescriber (and the provided Dosage section content is not available).
Contradictions
Important Omissions
Pediatric indication (patients 12 years of age and older) and the full indication phrasing including 'when those therapies are not advisable.'
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The main mismatches are about indication framing and dosing-schedule phrasing, not about contraindications, boxed warnings, or specific safety/monitoring statements (which are not present in the provided excerpt).
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several claims add detail not supported by the provided label excerpt (e.g., 'need systemic therapy,' 'most common form of eczema,' 'not a treatment for every type of rash,' and prescriber-set dosing schedule).
Suggested Improvement
Restrict indication language to the label excerpt (moderate-to-severe atopic dermatitis with inadequate control on topical prescription therapies or when those therapies are not advisable) and avoid stating or implying dosing details not present in the provided label text.